These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 318211)

  • 21. Chemotherapy of an experimental Bacteroides fragilis infection in mice.
    Walker CB; Nitzan D; Wilkins TD
    Antimicrob Agents Chemother; 1977 Mar; 11(3):435-40. PubMed ID: 855998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility of aerobic and anaerobic Gram-negative rods to cefoxitin and related compounds.
    Yeivin R; Peretz J; Sacks T
    Isr J Med Sci; 1979 Oct; 15(10):856-8. PubMed ID: 521267
    [No Abstract]   [Full Text] [Related]  

  • 24. Sensitivity of Bacteroides species to modern antimicrobial preparations.
    Závadová M; Tynková S; Adensámová J; Brezinová L
    J Hyg Epidemiol Microbiol Immunol; 1983; 27(1):51-9. PubMed ID: 6602163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variations in susceptibility to latamoxef(moxalactam) and cefoxitin within the Bacteroides fragilis group.
    Eley A; Greenwood D
    J Antimicrob Chemother; 1984 Mar; 13(3):245-55. PubMed ID: 6725175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of BL-S786 with cephalothin, cefamandole and cefoxitin in vitro and in treatment of experimental infections in mice.
    Goering RV; Sanders CC; Sanders W
    J Antibiot (Tokyo); 1978 Apr; 31(4):363-72. PubMed ID: 306989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of Anaerobic bacteria to carbenicillin, cefoxitin, and related drugs.
    Sutter VL; Finegold SM
    J Infect Dis; 1975 Apr; 131(4):417-22. PubMed ID: 804023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Augmentation effect of clavulanic acid with penicillin, cephalothin and ticarcillin against Bacteroides fragilis.
    Bansal MB; Chuah SK; Oryema-Lalobo M; Thadepalli H
    Chemotherapy; 1985; 31(3):173-7. PubMed ID: 3996086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibiotic levels in infected and sterile subcutaneous abscesses in mice.
    Joiner KA; Lowe BR; Dzink JL; Bartlett JG
    J Infect Dis; 1981 Mar; 143(3):487-94. PubMed ID: 6453169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the in-vivo efficacy of Sch 34343.
    Loebenberg D; Moss EL; Rudeen J; Menzel F; Hare RS; Oden EM; Lin CC; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():207-18. PubMed ID: 3897173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro protection of group A beta-hemolytic streptococci from penicillin and cephalothin by Bacteroides fragilis.
    Brook I; Yokum P
    Chemotherapy; 1983; 29(1):18-23. PubMed ID: 6339177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of free and liposome-encapsulated cefoxitin in experimental intra-abdominal sepsis in rats.
    Kresta A; Shek PN; Odumeru J; Bohnen JM
    J Pharm Pharmacol; 1993 Sep; 45(9):779-83. PubMed ID: 7903364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased resistance to cefoxitin and cefotetan among Bacteroides fragilis isolates from abdominal sources in patients undergoing surgery.
    Ehrenkranz NJ; Alfonso B
    Clin Infect Dis; 1993 Dec; 17(6):1080-2. PubMed ID: 8110948
    [No Abstract]   [Full Text] [Related]  

  • 34. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis.
    Snydman DR; Cuchural GJ; McDermott L; Gill M
    Antimicrob Agents Chemother; 1992 Mar; 36(3):540-4. PubMed ID: 1622162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the E-test for susceptibility testing of the Bacteroides fragilis group. Danish study group.
    Bremmelgaard A; Jansen JE; Justesen T; Gottschau A
    APMIS; 1994 Jun; 102(6):446-50. PubMed ID: 8068304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
    Bartlett JG; Dezfulian M; Joiner K
    Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of two beta-lactam antibiotics against strains of the Bacteroides fragilis group isolated from humans and from Callithrix penicillata marmosets.
    Avila-Campos MJ; de Carvalho MA; Veiga-Damasceno CA; Osório-Cisalpino E
    Rev Latinoam Microbiol; 1994; 36(3):159-62. PubMed ID: 7709091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies with cefuroxime and cefoxitin.
    Geddes AM; McGhie D; Ball AP; Gould I
    Scand J Infect Dis Suppl; 1978; (13):78-81. PubMed ID: 308260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increasing antibiotic dose decreases polymicrobial infection after hemorrhagic shock.
    Livingston DH; Malangoni MA
    Surg Gynecol Obstet; 1993 May; 176(5):418-22. PubMed ID: 8480263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A decisive period in cefoxitin prophylaxis of experimental synergistic wound infection produced by Bacteroides fragilis and Escherichia coli.
    Shapiro M; Sacks T
    Isr J Med Sci; 1982 Aug; 18(8):863-5. PubMed ID: 6749759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.